While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration.

No longer a mere assistant who carries out the commands of DNA, RNA takes the lead in emerging therapeutics.

After years of development, Isomorphic Labs says its AI-created drugs are nearly ready for human trials. Isomorphic Labs, the ...

The development of prodrugs — chemically modified versions of pharmacologically active agents that must undergo transformationin vivoto release the active drug — is a well-established strategy ...

Google DeepMind's Isomorphic Labs is preparing for human trials of AI-designed drugs, marking a significant advancement in ...

Industry Trends Published: September 1999 Cardiovascular disease drug discovery Aris Persidis Nature Biotechnology 17, 930–931 (1999) Cite this article ...

A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But ...

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are ...

Inside our cells, ribosomes—the tireless "protein factories" of life—have just shown off a new skill they haven't used in ...

A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts ...

At the ISC High Performance Conference in Germany, the intersection of quantum computing and scientific discovery was the focus of several talks and presentations, revealing an emerging future in ...

UB scientists Ram Samudrala, PhD, and Zackary M. Falls, PhD, talk about the new platform to make drug discovery faster and less expensive while also being safe and effective.